Enbrel® in Psoriatic Arthritis
Phase 4
Completed
- Conditions
- Psoriasis
- Registration Number
- NCT00111124
- Lead Sponsor
- Amgen
- Brief Summary
This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of subjects achieving a status on the Physician Global Assessment of Psoriasis of ""mild"" or better at week 24.
- Secondary Outcome Measures
Name Time Method Patient Global Assessment of Psoriasis Patient Global Assessment of Joint Pain Financial impact of therapy on disease as measured by Patient Pharmacoeconomic Questionnaire Serious Adverse Events Patient Global Assessment of Joint Disease Patient Assessment of Morning Stiffness Duration Quality of life and disability as measured by the DLQI and HAQ